Ignite Creation Date:
2024-05-06 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03133741
Status:
COMPLETED
Last Update Posted:
2017-11-01
First Post:
2017-04-25
Brief Title:
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
Sponsor:
University Hospital Gentofte Copenhagen
Organization:
University Hospital Gentofte Copenhagen
Study Overview
Official Title:
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist GA-3
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GA-3
Brief Summary:
Delinieation of GIPs effects during an oral glucose tolerance test OGTT in humans using GIP receptor antagonisation
Detailed Description:
Aim To evaluate the role of GIPR signalling in postprandial physiology including bone and glucose homeostasis using a naturally occurring GIP fragment GIP-A which antagonises the GIPR
Eighteen healthy men age 18-70 years BMI 19-35 kgm2 with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised double-blinded placebo-controlled cross-over study Study consists of four study days with concomitant infusions of A GIP-A B GLP-1 receptor antagonist Exendin9-39 C GIP-A Exendin9-39 or D saline placebo
Eighteen healthy men age 18-70 years BMI 19-35 kgm2 with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised double-blinded placebo-controlled cross-over study Study consists of four study days with concomitant infusions of A GIP-A B GLP-1 receptor antagonist Exendin9-39 C GIP-A Exendin9-39 or D saline placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None